The Peter Attia Drive

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter explores the complex and often misunderstood world of genetic testing, building a practical framework for understanding what these tests can and cannot actually tell us about health and disease. He explains why some genetic findings can be genuinely life-changing while many others offer information that is far more probabilistic than deterministic, and why directly measuring the phenotype is often more valuable than inferring risk from DNA alone. Peter examines where genetics can provide meaningful insight across the major disease categories and where its predictive power is far more limited than many people assume. He also discusses how to think critically about different types of genetic tests, how to interpret results in the proper context, and how to avoid the common trap of accumulating more genetic information without gaining greater clarity or actionable insight.

We discuss:

• Genetic testing: understanding what it can reveal, where it falls short, and how to think about its clinical value [1:45];
• The Human Genome Project: why decoding DNA did not immediately unlock the mysteries of disease [4:15];
• The limitations of genetic testing: probabilistic risk, interpretive uncertainty, and the importance of phenotype [9:30];
• Questions to ask when considering genetic testing [15:45];
• Genetic testing in cardiovascular and metabolic disease: when genotype adds value beyond phenotype [17:00];
• Genetic testing for inherited cardiac conditions: identifying hidden risk beyond routine screening [21:45];
• Genetic testing for cancer risk: inherited syndromes, clinical utility, and the limits of consumer testing [24:00];
• Genetic testing for neurodegenerative disease: risk prediction, planning, and the challenge of limited actionability [28:45];
• Functional medicine genetic testing: the gap between biological plausibility and clinical evidence, and the supplement protocols that aren't supported by evidence [32:45];
• Pharmacogenetics: using genetic testing to guide medication selection and safety [38:45];
• A framework for evaluating genetic tests according to effect size and clinical actionability [41:45];
• The major types of genetic tests, and how each should be matched to the clinical question being asked [43:30];
• Interpreting genetic test results: choosing the right testing laboratory and understanding what the findings actually mean [49:45];
• Framework summary: why genetic testing is most valuable when it is guided by a clear question, matched with the appropriate test, and capable of meaningfully influencing decisions [56:45]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter takes a deep dive into colorectal cancer (CRC) screening, explaining why it is one of the most preventable cancers and why getting screening right can have life-saving implications. He walks through how colorectal cancer develops and why it is uniquely well-suited to early detection and prevention, with a particular emphasis on the dual role of colonoscopy as both a diagnostic and therapeutic tool. Peter also examines the concerning rise in early-onset CRC among younger adults, highlighting why awareness and timely screening matter more than ever. The episode provides a practical guide to preparing for and evaluating the quality of a colonoscopy, including how to think about appropriate screening intervals and the real risks and tradeoffs involved. Finally, Peter explores the expanding landscape of non-invasive screening options, offering clear insight into what these alternatives can and cannot do so listeners can make informed decisions about their care at any age.

We discuss:

• CRC statistics and goals for this episode [1:00];
• Colorectal cancer development: polyp progression, risk types, and the window for prevention [4:00];
• Why colorectal cancer is uniquely screenable: direct visualization and the dual role of colonoscopy [6:30];
• Colonoscopy effectiveness: prevention through polyp removal and interpreting the NordICC trial data [8:15];
• Rising colorectal cancer in younger adults: trends, possible causes, and the case for earlier screening [12:15];
• Colonoscopy preparation: why bowel prep matters and how newer options improve the experience [16:45];
• Colonoscopy quality, polyp miss rates, and personalized screening intervals [20:00];
• Colonoscopy risks versus colorectal cancer risk: understanding the true risk-benefit tradeoff [29:30];
• Non-invasive screening options for CRC: benefits, limitations, and their role alongside colonoscopy [37:00];
• Colorectal cancer prevention principles: why screening matters and the role of colonoscopy [39:30]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it's possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #84 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

• Topics overview [1:15];
• Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30];
• Peter's views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30];
• Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00];
• Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00];
• Whether someone can be overweight yet metabolically healthy, and how fat distribution influences metabolic risk [26:45];
• Strength training with limited time: how to maximize results with intensity and efficiency [30:00];
• Designing a sustainable exercise routine: balancing volume, recovery, and enjoyment over time [34:45];
• Reducing dementia risk: prioritizing exercise, sleep, and cardiometabolic health based on individual gaps [38:00];
• Peter's current skepticism toward NAD-related supplements and what evidence would be needed to change his view [40:45];
• Hydration and electrolytes: factors that impact needs and when supplementation might be necessary [43:30]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter explores one of the most foundational topics underlying nearly everything discussed on the podcast: how to think scientifically. Framed as an introspective deep dive, he examines why scientific thinking is inherently difficult for humans, the cognitive biases and tendencies that make it challenging to separate belief from evidence, and why these challenges are even more consequential in today's environment saturated with misinformation. He also offers a framework for improving our ability to evaluate claims, question assumptions, and identify a personal panel of experts, providing listeners with practical tools to become more disciplined and effective thinkers.

We discuss:

• Topics to be covered and goals for this episode [2:00];
• Scientific thinking: hypotheses, uncertainty, and the process of ruling out explanations [3:45];
• How scientific knowledge differs from mathematical proof: useful approximations, evolving evidence, and acting under uncertainty [8:00];
• Why scientific thinking is difficult: evolution, social instincts, and the need for deliberate practice [13:30];
• Systems and tools designed to correct human bias [18:15];
• How to think scientifically pt. 1: Notice when you're feeling certain [20:30];
• How to think scientifically pt. 2: Judge the process, not just the conclusion [23:00];
• How to think scientifically pt. 3: Notice when identity is shaping your beliefs [28:15];
• How to think scientifically pt. 4: Don't confuse criticism with understanding [33:45];
• How to think scientifically pt. 5: Outsource your thinking carefully [36:15];
• Evaluating who to trust: incentives, consensus, and red flags in scientific credibility [45:15];
• Science as a self-correcting system: why updating with evidence is a strength, not a weakness [49:00];
• The key principles of scientific thinking, and a practical framework for evaluating claims and improving judgment [50:45]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality.

We discuss:

• The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30];
• PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30];
• The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00];
• How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00];
• Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00];
• Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30];
• Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45];
• Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45];
• How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00];
• The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #83 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

• Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];
• What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30];
• A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00];
• Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15];
• Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15];
• SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00];
• Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45];
• Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30];
• Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15];
• CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30];
• Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45];
• BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15];
• Other popular "gray market" peptides and why they mostly fail when under scrutiny [1:11:15];
• How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00];
• Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00];
• Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45];
• Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45];
• The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes.

We discuss:

• Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00];
• How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00];
• The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45];
• The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45];
• Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15];
• The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00];
• The DO-HEALTH study results: findings, takeaways, and open questions [27:45];
• The DunedinPACNI study: how the model was developed and what it may add to the field [35:00];
• The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes [48:00];
• Why aging clocks are not yet reliable as consumer tools and why traditional health metrics still matter most [52:00]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #82 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

• Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance [1:30];
• How health priorities and training strategies should evolve from early adulthood through older age [2:45];
• Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00];
• Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00];
• How to use wearable data effectively: when it's helpful, when it's not, and how to avoid over-reliance [19:00];
• DEXA scans: timing, interpretation, and limitations in body composition and bone density tracking [23:00];
• Best practices for building sustainable health habits [30:15];
• How to train your balance and stability [33:30];
• How to recover from injuries and use setbacks to build strength and resilience [36:15];
• High protein intake and the impact on mTOR: evaluating mechanisms versus real-world evidence on longevity [38:30];
• Diet soda and artificial sweeteners: evaluating risks, benefits, and the importance of context [47:00];
• How to balance enjoying life today with making choices that support long-term health and longevity [51:45]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why earlier versions of these drugs failed—sometimes dramatically—and breaks down the key clinical trials designed to evaluate their impact on cardiovascular risk. Peter examines how obicetrapib influences major lipid biomarkers, including LDL cholesterol and lipoprotein(a) [Lp(a)], and discusses emerging evidence from a study that explored the drug's effects on Alzheimer's-related blood biomarkers. He also highlights intriguing findings in individuals carrying the APOE4 allele and reflects on what these early results may mean for both cardiovascular disease prevention and potential implications for Alzheimer's risk, as well as how he is thinking about this therapy in the context of caring for his own patients.

We discuss:

• Introducing obicetrapib: CETP inhibitor history, lipid biology, and early Alzheimer's biomarker signals in APOE4 carriers [2:15];
• CETP biology explained: lipoproteins, reverse cholesterol transport, and how CETP inhibition alters HDL and LDL particles [5:15];
• The early CETP inhibitor story: why raising HDL cholesterol alone failed to deliver cardiovascular protection [13:45];
• The rise and fall of early CETP inhibitors: torcetrapib, dalcetrapib, evacetrapib, and anacetrapib [18:30];
• Why obicetrapib may succeed where earlier CETP inhibitors failed [23:30];
• The BROADWAY trial: obicetrapib's effects on LDL, ApoB, Lp(a), and residual cardiovascular risk [26:00];
• Brain lipid metabolism and APOE4: how CETP inhibition may influence cholesterol transport in Alzheimer's disease [30:45];
• Findings from the substudy of the BROADWAY trial which looked at changes in biomarkers of Alzheimer's disease [40:00];
• Interpreting the BROADWAY Alzheimer's biomarker results: limitations, cautious optimism, and the need for a dedicated prevention trial [46:45];
• Why Peter is optimistic about obicetrapib: cardiovascular benefits, Lp(a) reduction, and the path toward approval [50:00]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Layne Norton is a nutrition scientist and accomplished power athlete,who returns to The Drive for a conversation that departs from the show's usual format. In this episode, Layne presents the evidence-based case that seed oils are not uniquely harmful under isocaloric conditions, while Peter steelmans the strongest versions of the opposing argument that seed oils are inherently harmful. They examine how scientific bias and evidence are evaluated, revisit the historical randomized controlled trials that shaped the seed oil controversy, and explore the mechanistic biology underlying LDL oxidation and atherosclerosis. Along the way, Layne unpacks the chemistry and processing of modern seed oils, assesses evolutionary and ancestral nutrition arguments, clarifies the relationship between seed oils, ultra-processed foods, and contemporary dietary patterns, and situates these questions within the larger context of lifestyle factors that drive cardiometabolic health. Layne concludes by offering practical considerations around dietary fats, cooking oils, and real-world food choices.

We discuss:

• The idea behind this episode, biases, and evidence-based thinking [5:15];
• The four core arguments behind claims that seed oils are harmful [12:30];
• The Minnesota Coronary Experiment (MCE) [14:30];
• The differences among saturated, monounsaturated, polyunsaturated, and trans fats, and why those differences matter for cardiovascular disease [18:30];
• Missing trans fat data as a confounder in the Minnesota Coronary Experiment, other limitations of that study, and the challenge detecting meaningful differences in hard outcomes through nutrition research [24:00];
• The Sydney Diet Heart Study (SDHS): an attempt to address the "duration problem" by enrolling a much higher-risk population [28:30];
• Debating whether evidence from randomized trials supports the idea that seed oils are uniquely harmful once major confounders are removed [34:00];
• The Rose Corn Oil trial: an often-cited study used to argue against polyunsaturated fats [36:30];
• Three studies where replacing saturated fat with polyunsaturated fat produced different results than earlier trials [41:30];
• Layne's explanation for why the evidence is pointing towards cardiovascular risk reduction when substituting polyunsaturated fat for saturated fat [47:30];
• What Mendelian randomization says about the causal role of LDL cholesterol in ASCVD [56:45];
• The compounding effects of life-long exposure to high LDL cholesterol [1:06:45];
• Does the linoleic acid (omega-6) content of seed oils cause inflammation? [1:13:45];
• Does the linoleic acid (omega-6) content of seed oils increase oxidized LDL? [1:19:30];
• Layne's analogy to explain why lower LDL particle number outweighs higher per-particle oxidation risk when comparing polyunsaturated fats to saturated fats [1:26:15];
• The role of oxidized LDL in CVD: exploring differences in a diet high in polyunsaturated fat (seed oils) versus high in saturated fat [1:28:00];
• Examining whether industrial processing and solvent extraction of seed oils—especially residual hexane—could plausibly cause long-term harm [1:34:00];
• The evolutionary and "ancestral diet" argument against seed oils [1:40:45];
• Weighing concerns about industrial processing of seed oils against the totality of metabolic and cardiovascular evidence [1:47:30];
• Practical considerations around dietary fats, cooking oils, and real-world food choices [1:50:00];
• Comparing the health impact of seed oils with that of caloric intake and activity levels, and how to prioritize interventions [2:00:15];
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube